trending Market Intelligence /marketintelligence/en/news-insights/trending/tr3bikckzwjcuz0bclqg1g2 content esgSubNav
In This List

Medtronic's drug-coated balloons snag US FDA approval

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Medtronic's drug-coated balloons snag US FDA approval

Two versions of Medtronic PLC's IN.PACT Admiral balloons to treat lesions in blocked arteries have received approval from the U.S. Food and Drug Administration.

The Dublin, Ireland company's drug-coated balloons can be used to treat 200-millimeter and 250-millimeter lesions in patients with peripheral artery disease, a buildup of fatty deposits that lead to narrowed arteries and less blood flow.

The FDA approved a 360mm version of the device in April.

In all three cases, the balloons are used in the superficial femoral artery, the main artery running through the leg and an important pathway for oxygenated blood to flow through the limb.